On December 21, 2020, the Certificate of Supplementary Protection Regulations were amended to add the United Kingdom as a "prescribed country"

The Canadian Intellectual Property Organization today released for comment their draft regulations designed to implement amendments to the Trademarks Act passed in 2014...

On November 22, 2017 the Federal Court issued a judgment granting Apotex's motion under s. 6(5)(b) of the PMNOC Regulations: Bristol-Myers Squibb et al v Apotex Inc et al, 2017 FC 1061.

On April 1, 2021, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,564 to $9,756 in accordance with subsection 9(1) of the Certificate of Supplementary...

The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.

That the U.S. Food and Drug Administration had previously approved a different drug product with higher levels of SLS did not render the decision unreasonable.

As previously reported, the Patented Medicine Prices Review Board (PMPRB) extended the consultation period for its draft Guidelines to February 14, 2020. Submissions from the consultation...

The Patented Medicine Prices Review Board (PMPRB) has released its 7th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20.

On April 28, 2017, the Supreme Court of Canada dismissed Apotex's application for leave to appeal a decision of the Federal Court of Appeal

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) ...

Scott MacKendrick and Andrew McIntosh's article "2023's Procedural Developments in IP Litigation" was published in the Toronto Law Journal.

On November 2, 2015, the CBSA released an updated version of its D Memorandum on Copyright and Trademarks (D19-4-1).

This informative podcast breaks down the key developments of AI in chemistry and explores the nuances of intellectual property in the field of Chemical AI.

We previously reported on proposed amendments to the Patented Medicines Regulations released on December 2, 2017.

On October 26, 2017, the Federal Minister of Health tabled the 2016 Annual Report of the PMPRB with the Clerks of the House of Commons and the Senate.

On October 7, 2021, the Supreme Court of Canada denied leave to Apotex.

Earlier this year we reported on a decision of the Federal Court of Appeal in which the University of Alberta sought to revive an abandoned patent application after the reinstatement period had expired.

Join us as we celebrate International Women's Day with our new podcast led by three intellectual property professionals. Hear from associates Alissa Hyppolite, Shaivi Bhatt, and Parnian Soltanipanah...

oin us as we support Neurodiversity Celebration Week. In this podcast, partner Micheline Gravelle chats with partner Bhupinder Randhawa about his views and experiences in working with ADHD in a law firm environment.

New Court Proceedings.